Publicaciones en las que colabora con José Alcamí Pertejo (11)

2021

  1. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

    The Lancet, Vol. 398, Núm. 10295, pp. 121-130

2019

  1. Novel association of five HLA alleles with HIV-1 progression in Spanish long-term non progressor patients

    PLoS ONE, Vol. 14, Núm. 8

2018

  1. Factors leading to the loss of natural elite control of HIV-1 infection

    Journal of Virology, Vol. 92, Núm. 5

2016

  1. Rate and predictors of progression in elite and viremic HIV-1 controllers

    AIDS, Vol. 30, Núm. 8, pp. 1209-1220

2013

  1. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

  2. Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists

    AIDS Reviews, Vol. 14, Núm. 3, pp. 208-217

2010

  1. Genotypic determination of HIV tropism - Clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists

    AIDS Reviews, Vol. 12, Núm. 3, pp. 135-148

2009

  1. The Spanish HIV BioBank: A model of cooperative HIV research

    Retrovirology, Vol. 6

2008

  1. Guadalupe manifesto: For the recognition of the specialty of infectious diseases in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 26, Núm. SUPPL. 15, pp. 65-66

2001

  1. GESIDA Consensus document on the use of resistance studies in clinical practice

    Enfermedades infecciosas y microbiología clínica